A C Moses Selected Research

Glucose (Dextrose)

2/2008	Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine.
8/2005	Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

A C Moses Research Topics

Disease

3	Type 2 Diabetes Mellitus (MODY) 05/2015 - 08/2005
2	Pain (Aches) 08/2005 - 04/2000
2	Edema (Dropsy) 08/2005 - 04/2000
1	Insulin Resistance 08/2005
1	Hyperglycemia 08/2005
1	Arthralgia (Joint Pain) 08/2005
1	Papilledema 04/2000
1	Bell Palsy (Bell's Palsy) 04/2000
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 04/2000
1	Headache (Headaches) 04/2000
1	Bone Resorption 02/2000

Drug/Important Bio-Agent (IBA)

2	Glucose (Dextrose)FDA LinkGeneric 02/2008 - 08/2005
2	Insulin-Like Growth Factor I (IGF-1)IBA 08/2005 - 04/2000
2	Insulin (Novolin)FDA Link 08/2005 - 04/2000
1	Liraglutide FDA Link 05/2015
1	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 05/2015
1	1,5-anhydroglucitolIBA 02/2008
1	insulin aspart protamine drug combination 30:70 insulin aspartIBA 02/2008
1	Insulin Glargine (Lantus)FDA Link 02/2008
1	Carrier Proteins (Binding Protein)IBA 08/2005
1	Insulin-Like Growth Factor Binding Protein 3IBA 08/2005
1	Biological ProductsIBA 04/2000
1	Insulin-Like PeptidesIBA 04/2000
1	Insulin-Like Growth Factor Binding ProteinsIBA 04/2000
1	Diphosphonates (Bisphosphonates)IBA 02/2000

Therapy/Procedure

1	Therapeutics 02/2000